HomeCompareAMNB vs ABBV

AMNB vs ABBV: Dividend Comparison 2026

AMNB yields 2.51% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $70.4K in total portfolio value
10 years
AMNB
AMNB
● Live price
2.51%
Share price
$47.76
Annual div
$1.20
5Y div CAGR
20%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.9K
Annual income
$2,341.30
Full AMNB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AMNB vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMNBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMNB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMNB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMNB
Annual income on $10K today (after 15% tax)
$213.57/yr
After 10yr DRIP, annual income (after tax)
$1,990.11/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,065.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMNB + ABBV for your $10,000?

AMNB: 50%ABBV: 50%
100% ABBV50/50100% AMNB
Portfolio after 10yr
$67.1K
Annual income
$13,556.53/yr
Blended yield
20.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AMNB
Analyst Ratings
1
Buy
3
Hold
Consensus: Hold
Altman Z
-0.0
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMNB buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMNBABBV
Forward yield2.51%3.06%
Annual dividend / share$1.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR20%40.6%
Portfolio after 10y$31.9K$102.3K
Annual income after 10y$2,341.30$24,771.77
Total dividends collected$10.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: AMNB vs ABBV ($10,000, DRIP)

YearAMNB PortfolioAMNB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,002$301.51$11,550$430.00$548.00ABBV
2$12,144$372.00$13,472$627.96$1.3KABBV
3$13,454$460.51$15,906$926.08$2.5KABBV
4$14,968$572.20$19,071$1,382.55$4.1KABBV
5$16,730$713.93$23,302$2,095.81$6.6KABBV
6$18,796$894.91$29,150$3,237.93$10.4KABBV
7$21,239$1,127.58$37,536$5,121.41$16.3KABBV
8$24,155$1,428.95$50,079$8,338.38$25.9KABBV
9$27,668$1,822.56$69,753$14,065.80$42.1KABBV
10$31,946$2,341.30$102,337$24,771.77$70.4KABBV

AMNB vs ABBV: Complete Analysis 2026

AMNBStock

American National Bankshares Inc. operates as the bank holding company for American National Bank and Trust Company that provides financial products and services. The company operates in two segments, Community Banking and Wealth Management. It accepts deposit products, including checking, money market, savings, and consumer and commercial time deposits. The company's loan products comprise commercial and residential real estate loans, commercial loans to small and medium-sized businesses, construction and land development loans, home equity loans, mortgage loans, and consumer loans. It also offers wealth management services, including estate planning, trust account administration, and retail brokerage services; investment management services, such as purchasing equity, fixed income, and mutual fund investments for customer accounts; online and telephone banking services; and insurance services, as well as operates 37 automated teller machines. As of December 31, 2021, the company operated 26 banking offices in south central Virginia and north central North Carolina; and one loan production office in Roanoke, Virginia. American National Bankshares Inc. was founded in 1909 and is based in Danville, Virginia.

Full AMNB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AMNB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMNB vs SCHDAMNB vs JEPIAMNB vs OAMNB vs KOAMNB vs MAINAMNB vs JNJAMNB vs MRKAMNB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.